Press releases

October 2020

Notice of extraordinary shareholders’ meeting in SynAct Pharma AB

The shareholders of SynAct Pharma AB, Reg. No. 559058-4826, are hereby invited to attend the extraordinary shareholders’ meeting to be held at the premises of Setterwalls Advokatbyrå AB at Stortorget 23... Read more

Shareholders of SynAct Pharma proposes Uli Hacksell as new board member

Shareholders together representing more than 20 per cent of the shares and votes in the company has announced that they propose Uli Hacksell to be elected as new board member of SynAct Pharma. For this... Read more

SynAct Pharma terminates agreement for liquidity providing

SynAct Pharma AB (publ) today announced that it has terminated its agreement with Sedemera Fondkommission to act as the company’s liquidity provider. Read more

English version of PR published 20201012 at 07.33AM     SynAct Pharma completes part 1 of clinical phase II study with AP1189 in Rheumatoid Arthritis

SynAct Pharma AB ("SynAct") today announced that dosing of the leading candidate drug AP1189 was successfully completed in the second cohort (100 mg dose level) in part 1 of the company’s Phase IIa st... Read more

September 2020

SynAct Pharma Initiates Phase II Study with AP1189 for the Treatment of ARDS in COVID-19 Patients

SynAct Pharma AB ("SynAct Pharma") today announced the initiation of a Phase II clinical study to evaluate the safety and efficacy of the company’s lead candidate drug AP1189 in adults diagnosed with C... Read more

SynAct Pharma informs that the recruitment to part 1 in the Clinical Phase II study with AP1189 in Rheumatoid Arthritis is completed

SynAct Pharma AB ("SynAct") today announces that recruitment to the second cohort in part 1 of the company’s Phase IIa study in patients with Rheumatoid Arthritis (RA) with high disease activity has be... Read more

SynAct Pharma Informs about Termination of Coverage Agreement with Redeye

SynAct Pharma AB ("SynAct Pharma") hereby informs that the company has terminated the agreement with Redeye relating to the coverage of the company. For further information, please contact: Jeppe Øvlesen                                                                                ... Read more

August 2020

SynAct Pharma Initiates RESOVIR: Scientific and clinical Collaboration to Explore AP1189 in Viral Infections

SynAct Pharma AB ("SynAct Pharma") hereby announces that the company together with Prof Mauro Teixeira, MD, PhD, Universidade Federal de Minas, Belo Horizonte, Brazil and Prof Mauro Perretti, PhD William... Read more

July 2020

Synact Pharma announces outcome in the exercise of warrants, will receive approximately MSEK 32.4

On Wednesday, July 22, 2020, the exercise period for SynAct Pharma AB's (“SynAct” or “the Company”) warrants of series TO 2 (“TO 2”) ended. A total of 4,839,860 warrants of series TO 2 were exercised, ... Read more

SynAct Pharma AB: Update on SynAct Pharma´s Clinical Phase II study with AP1189 in Rheumatoid Arthritis

SynAct Pharma AB ("SynAct") today announces that the company is making progress in the second and final dose level (100 mg) in part 1 in patients with a Rheumatoid Arthritis with high disease activity... Read more

June 2020

SynAct Pharma announces that the exercise period for warrants of the TO 2 series will start on July 1, 2020

SynAct Pharma AB ("SynAct" or "The Company") today announces that the exercise period for warrants of series TO 2 ("TO 2") will start on 1 July 2020. The exercise period runs from 1 July to 22 July 2020.... Read more

SynAct Pharma has initiated the Phase II clinical study with AP1189 in Nephrotic Syndrome

SynAct Pharma AB ("SynAct") today announced that the company has initiated a Phase II clinical study with the AP1189 compound in idiopathic membranous nephropathy patients with Nephrotic Syndrome. Read more

SynAct Pharma’s Board of Directors and management sign subscription commitment for warrant exercise of series TO 2

SynAct Pharma AB ("SynAct") today announces that the company's Board of Directors and management have agreed to subscribe for 100 percent of the Board of Directors and management's total holding of warrants... Read more

SynAct Pharma´s clinical trial application for AP1189 in Nephrotic Syndrome approved by the Danish Medical Agency

SynAct Pharma AB ("SynAct") today announced that the Danish Medical Agency has approved the company’s clinical trial application (CTA) for a Phase IIa study in idiopathic membranous nephropathy patients w... Read more

May 2020

SynAct Pharma files patent application for combination of AP1189 and Methotrexate for treatment of RA and other arthritic diseases

SynAct Pharma AB (“SynAct”) today announces that the company has filed an international patent application under the Patent Coordination Treaty (PCT), to cover combination treatment with the company’s lead ... Read more

Majoritetsägare i SynAct Pharma förlänger lock-up

SynAct Pharma AB (”SynAct”) meddelar härmed att alla personer i styrelse och ledning i bolaget har ingått avtal om en förlängning av lock-up om tolv månader. Totalt motsvarar lock-up-avtalen minimum 25 proce... Read more

SynAct presents initial data from the first part of the Phase II study within RA and gives an update on its progression

· The first of two tested doses (50 mg) identified to be safe and well-tolerated. · The blinded review revealed that patients in the study form two groups based on changes in their clinical disease a... Read more

April 2020

SynAct Pharma applies for patent for AP1189 within COVID-19

SynAct Pharma AB ("SynAct") hereby announces that the company has filed a patent application to the European Patent Office (EPO) covering the use of AP1189 for the treatment of COVID-19 infection, including... Read more

March 2020

SynAct Pharma submits clinical trial application for AP1189 in Nephrotic Syndrome

SynAct Pharma AB ("SynAct") today announced that the company has submitted a clinical trial application (CTA) to the Danish Medicines Agency to initiate a Phase IIa study with its lead candidate drug AP1189... Read more

Translation – UK version of Swedish press release – published 08.00 AM. today – SynAct Pharma investigates the possibility of AP1189 as additional therapy in hospitalized patients with COVID-19

SynAct Pharma AB ("SynAct") today announced that the company investigates the possibility of developing its clinical anti-inflammatory lead candidate drug AP1189 as an additional therapy in hospitalized... Read more